tiprankstipranks
Advertisement
Advertisement

ALDX Stock Latest News

Aldeyra Updates Reproxalap Outlook and Extends Cash Runway
Company AnnouncementsAldeyra Updates Reproxalap Outlook and Extends Cash Runway
14d ago
8K
ALDX
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures 
PremiumClass Action
Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures 
23d ago
ALDX
Aldeyra Therapeutics Announces Upcoming Board Member Departure
PremiumCompany Announcements
Aldeyra Therapeutics Announces Upcoming Board Member Departure
25d ago
8K
ALDX
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
PremiumClass Action
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky
28d ago
ALDX
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
PremiumClass Action
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
1M ago
ALDX
Aldeyra Repays Hercules Loan, Boosting Financial Flexibility
PremiumCompany AnnouncementsAldeyra Repays Hercules Loan, Boosting Financial Flexibility
1M ago
8K
ALDX
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
Premium
Ratings
Maintaining Hold on Aldeyra as FDA CRL Clouds Reproxalap’s Dry Eye Path and Lowers Approval Odds
2M ago
ALDX
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
2M ago
ALDX
Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up 3/17/26: Today’s Biggest Stock Market Stories!
2M ago
MA
MU
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
PremiumThe Fly
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
2M ago
ALDX
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
PremiumMarket News
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
2M ago
ALDX
FDA Issues Second Complete Response Letter for Reproxalap
PremiumCompany Announcements
FDA Issues Second Complete Response Letter for Reproxalap
2M ago
8K
ALDX
Aldeyra options imply 10.9% move in share price post-earnings
PremiumThe FlyAldeyra options imply 10.9% move in share price post-earnings
2M ago
ALDX
Aldeyra Therapeutics Announces Chief Development Officer Resignation
Premium
Company Announcements
Aldeyra Therapeutics Announces Chief Development Officer Resignation
4M ago
8K
ALDX
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
Premium
Ratings
Aldeyra Therapeutics: Buy Rating Affirmed Amid Promising Drug Development and Robust Investment Potential
5M ago
ALDX
Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
PremiumThe Fly
Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
5M ago
F
F
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
PremiumRatings
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
5M ago
ALDX
Unusually active option classes on open December 16th
PremiumThe Fly
Unusually active option classes on open December 16th
5M ago
F
BP
Aldeyra Therapeutics Faces FDA PDUFA Date Extension
PremiumCompany Announcements
Aldeyra Therapeutics Faces FDA PDUFA Date Extension
5M ago
8K
ALDX
Aldeyra announces PDUFA extension for Reproxalap
PremiumThe FlyAldeyra announces PDUFA extension for Reproxalap
5M ago
ALDX
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
Premium
Company Announcements
Aldeyra Therapeutics Completes Promising Phase 2 Trial for Alcohol-Associated Hepatitis
5M ago
ALDX
Aldeyra Therapeutics: Promising Advancements and Strategic Positioning Drive Buy Rating
Premium
Ratings
Aldeyra Therapeutics: Promising Advancements and Strategic Positioning Drive Buy Rating
6M ago
ALDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >